Clinical trial
Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as…
NCT00129376 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00129376 |
|---|---|
| Title | Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients |
| Official title | Multicenter Phase II Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel (T) as Neoadjuvant Treatment for Operable Stage II and IIIA Breast Cancer Patients |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Doxorubicin, Cyclophosphamide, Docetaxel |
| Enrollment | 63 |
| Start date | Feb 1, 2003 |
| Primary completion | Jul 1, 2005 |
| Completion | Feb 1, 2010 |
| First posted | Aug 11, 2005 |
| Last update posted | Jul 5, 2019 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: